statistiche ricercatore

PASSAMONTI, FRANCESCO

Distribuzione geografica

Continente	#
NA - Nord America	24.744
EU - Europa	10.497
AS - Asia	7.202
SA - Sud America	898
AF - Africa	103
Continente sconosciuto - Info sul continente non disponibili	14
OC - Oceania	7
Totale	43.465

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	24.535
IT - Italia	5.617
SG - Singapore	2.211
CN - Cina	1.619
UA - Ucraina	1.566
TR - Turchia	1.031
VN - Vietnam	1.024
HK - Hong Kong	759
BR - Brasile	737
SE - Svezia	698
IE - Irlanda	613
DE - Germania	425
GB - Regno Unito	381
FI - Finlandia	350
FR - Francia	326
RU - Federazione Russa	260
BD - Bangladesh	146
CA - Canada	110
IN - India	87
MX - Messico	72
JP - Giappone	62
AR - Argentina	61
PK - Pakistan	47
CZ - Repubblica Ceca	41
NL - Olanda	40
AT - Austria	35
IQ - Iraq	34
PL - Polonia	30
EC - Ecuador	28
ES - Italia	27
ZA - Sudafrica	27
ID - Indonesia	25
SA - Arabia Saudita	22
UZ - Uzbekistan	19
VE - Venezuela	17
LT - Lituania	15
CO - Colombia	14
MY - Malesia	14
BE - Belgio	13
CL - Cile	13
EG - Egitto	11
EU - Europa	11
JO - Giordania	11
KR - Corea	11
MA - Marocco	11
NG - Nigeria	11
DZ - Algeria	10
AE - Emirati Arabi Uniti	9
HU - Ungheria	9
KE - Kenya	9
PY - Paraguay	9
IR - Iran	8
NP - Nepal	8
PE - Perù	8
BG - Bulgaria	7
CH - Svizzera	7
ET - Etiopia	7
KZ - Kazakistan	7
LB - Libano	7
TW - Taiwan	7
UY - Uruguay	7
IL - Israele	6
NO - Norvegia	6
OM - Oman	6
RS - Serbia	6
TH - Thailandia	6
HN - Honduras	5
MD - Moldavia	5
SN - Senegal	5
TN - Tunisia	5
AU - Australia	4
AZ - Azerbaigian	4
BA - Bosnia-Erzegovina	4
JM - Giamaica	4
PH - Filippine	4
RO - Romania	4
CR - Costa Rica	3
DO - Repubblica Dominicana	3
GR - Grecia	3
NZ - Nuova Zelanda	3
TT - Trinidad e Tobago	3
AL - Albania	2
AO - Angola	2
BO - Bolivia	2
DK - Danimarca	2
GY - Guiana	2
KW - Kuwait	2
LU - Lussemburgo	2
PA - Panama	2
PR - Porto Rico	2
PS - Palestinian Territory	2
SK - Slovacchia (Repubblica Slovacca)	2
XK - ???statistics.table.value.countryCode.XK???	2
A2 - ???statistics.table.value.countryCode.A2???	1
BS - Bahamas	1
BW - Botswana	1
CI - Costa d'Avorio	1
GE - Georgia	1
GP - Guadalupe	1
GT - Guatemala	1
Totale	43.456

Salva come PNG Salva come JPEG

Città	#
Milan	4.211
Fairfield	3.291
Woodbridge	2.767
Houston	2.075
Ashburn	2.074
San Jose	1.590
Ann Arbor	1.578
Jacksonville	1.337
Seattle	1.334
Cambridge	1.176
Wilmington	1.124
Singapore	1.117
Hong Kong	745
Chandler	678
Dublin	610
Dallas	563
Princeton	525
Dearborn	479
Izmir	473
Nyköping	365
Boardman	337
The Dalles	315
Beijing	292
Dong Ket	271
Rome	245
Lauterbourg	235
San Diego	177
Ho Chi Minh City	160
Ogden	133
Hanoi	125
Los Angeles	108
London	98
New York	98
Como	84
Council Bluffs	82
Santa Clara	80
Guangzhou	79
Chicago	75
São Paulo	66
Washington	65
Redmond	64
Helsinki	61
Hefei	54
Mexico City	52
Orem	49
Kocaeli	48
Nanjing	45
Tokyo	45
Hangzhou	44
Munich	44
Kunming	37
Shanghai	36
Toronto	36
Zhengzhou	36
Da Nang	30
Tianjin	30
Brno	29
Kilburn	29
Norwalk	29
Rio de Janeiro	29
Montreal	28
San Francisco	28
Nuremberg	27
Brooklyn	26
Frankfurt am Main	26
Warsaw	26
Columbus	25
Redwood City	25
Atlanta	23
Boston	23
Jinan	23
Nanchang	22
Chennai	21
Düsseldorf	21
Phoenix	21
Haiphong	20
Ankara	19
Salt Lake City	19
Changsha	18
Denver	18
Johannesburg	18
Tashkent	18
Belo Horizonte	17
Rawalpindi	17
Verona	17
Poplar	16
Quito	16
Turku	16
Vienna	16
Dhaka	15
Acton	14
Amsterdam	14
Brasília	14
Chengdu	14
Manchester	14
Shenzhen	14
Biên Hòa	13
Brussels	13
Fuzhou	13
Shenyang	13
Totale	32.825

Salva come PNG Salva come JPEG

Nome	#
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm	290
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence	281
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.	270
Analysis of three screening methods for the detection of calreticulin gene mutations	267
A gain-of-function mutation of JAK2 in myeloproliferative disorders	263
Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: An analysis by the MPN QOL international working group	248
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts	246
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations	243
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis	243
European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.	240
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis	240
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN	238
Mutations and thrombosis in essential thrombocythemia: Prognostic interaction with age and thrombosis history	237
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms	232
Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study	231
Subcutaneous 'lipoma-like' B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT.	229
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.	228
New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma	228
Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs	228
Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group	225
Looking for CALR mutations in familial myeloproliferative neoplasms	222
ACUTE MYELOID LEUKEMIA (AML) HAVING EVOLVED FROM ESSENTIAL THROMBOCYTHEMIA (ET): DISTINCTIVE CHROMOSOME ABNORMALITIES IN PATIENTS TREATED WITH PIPOBROMAN OR HYDROXYUREA	220
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients.	219
Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients	217
A new acute myeloid leukemia case with STAT5B-RARA gene fusion due to 17q21.2 interstitial deletion	217
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients	216
Antiplatelet drugs for polycythaemia vera and essential thrombocythaemia	215
Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera	215
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis	215
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.	215
Mutational status of myeloproliferative neoplasms.	212
A novel germline JAK2 mutation in familial myeloproliferative neoplasms	211
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies	211
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients.	211
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.	211
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients.	208
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders	204
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia	204
The 'GGCC' haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera.	203
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms	203
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts	203
It is time to change thrombosis risk assessment for PV and ET?	200
Novel agents in indolent lymphomas	200
TREATMENT OF POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA: THE ROLE OF PIPOBROMAN.	199
Developments in diagnosis and treatment of essential thrombocythemia	198
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)	197
Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients	197
European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis: Haematologica 2012;97(3):360-5 - Comment	197
Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.	197
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis	197
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project	197
Standard care and investigational drugs in the treatment of myelofibrosis	197
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group	197
A prognostic model to predict survival in 867 WHO-defined essential thrombocythemia at diagnosis: a study by the IWG-MRT.	196
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons	196
Direct-Acting Antivirals During or After Immunochemotherapy in Hepatitis C Virus-Positive Diffuse Large B-Cell Lymphomas	196
Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia	195
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients	195
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis	195
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases	194
Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients	194
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders	194
What are RBC-transfusion-dependence and -independence?	194
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report	194
Role of the molecular staging and response in the management of follicular lymphoma patients	193
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2	193
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman.	193
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial	193
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome.	192
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)	191
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis	191
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.	190
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.	189
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients.	189
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study	189
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis	189
RBC-transfusion guidelines update	188
Disease anticipation in familial myeloproliferative neoplasms.	188
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy	187
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early /prefibrotic primary myelofibrosis.	187
Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma	187
How I treat polycythemia vera	187
Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden	187
JAK inhibitor in CALR-mutant myelofibrosis	186
The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group	186
Prognostic factors and models in polycythemia vera, essential thrombocythemia, and primary myelofibrosis	186
A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process	185
Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs	184
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub	184
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS.	183
Cardiovascular events and intensity of treatment in polycythemia vera	183
A final note about ibrutinib in relapsed or refractory CLL: Conclusive results from RESONATE sound definitely good!	182
Blast phase of essential thrombocythemia: A single center study.	181
Myeloproliferative Neoplasms	181
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations.	181
How to manage polycythemia vera	181
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment	180
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis	179
Primary leptomeningeal CNS lymphoma presenting as bilateral facial nerve palsy	178
New generation small-molecule inhibitors in myeloproliferative neoplasms	178
Totale	20.576

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	175.559
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	175.559

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	626	0	0	0	0	0	0	0	0	0	0	0	626
2021/2022	2.587	335	436	24	118	96	128	150	159	146	416	243	336
2022/2023	2.444	283	79	141	230	177	650	15	300	372	82	40	75
2023/2024	6.571	1.015	1.045	1.030	1.308	1.278	449	66	83	201	20	24	52
2024/2025	3.136	26	12	606	106	104	251	107	217	389	241	246	831
2025/2026	8.996	591	535	640	1.179	557	496	1.744	696	1.287	675	432	164
Totale													44.000